Comparison
Nicotinamide Riboside vs Testosterone
Side-by-side of Nicotinamide Riboside and Testosterone. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Nicotinamide Riboside
Nicotinamide riboside (NR) is the most-studied NAD+ precursor in humans. Sold as Niagen by Chromadex; raises plasma NAD+ 30-60% at 250-1,000 mg/day.
Testosterone
Testosterone replacement therapy for hypogonadism: TRAVERSE 2023 cardiovascular data, cypionate dosing, body composition gains, Schedule III status.
Effects at a glance
Nicotinamide Riboside
- •Most-studied NAD+ precursor in human trials; the original Niagen formulation by Chromadex
- •Plasma NAD+ rises 30-60% at 250-1,000 mg/day across multiple human PK trials
- •Martens 2018 reported reduced BP and arterial stiffness at 500 mg/day for 6 weeks
- •Dollerup 2018 found no insulin sensitivity change despite plasma NAD+ rise
- •Tissue NAD+ rise inconsistent; hard clinical endpoints not yet measured
- •Larger human safety database than NMN; comparable mechanistic effects
Testosterone
- •Primary androgen; FDA approved for hypogonadism with confirmed deficiency and symptoms
- •Testosterone Trials (2016) showed sexual function and bone density improvements in older hypogonadal men
- •TRAVERSE 2023 (n=5,246) found non-inferiority on MACE versus placebo, with higher AF and PE rates
- •Schedule III controlled substance in US; WADA banned in sport
- •Aromatizes to estradiol; converts to DHT via 5-alpha reductase; both metabolites matter clinically
- •Erythrocytosis (HCT above 54%) affects 5 to 25% of users and is the most common dose-limiting effect
Side-by-side
| Attribute | Nicotinamide Riboside | Testosterone |
|---|---|---|
| Category | supplement | hormone |
| Also known as | NR, Niagen, nicotinamide riboside chloride | TRT, testosterone replacement therapy, testosterone cypionate, testosterone enanthate, Androgel, Testim |
| Half-life (hr) ↗ | 8 | 192 |
| Typical dose (mg) ↗ | 500 | 150 |
| Dosing frequency | daily, typically morning | weekly to twice-weekly (cypionate/enanthate IM or SC); daily (topical, oral); every 3 to 6 months (pellet) |
| Routes | oral | intramuscular, subcutaneous, topical, buccal, subcutaneous (pellet), oral |
| Onset (hr) | 1 | 24 |
| Peak (hr) | 4 | 72 |
| Molecular weight | 255.25 | 288.42 |
| Molecular formula | C11H15N2O5 | C19H28O2 |
| Mechanism | NAD+ precursor via salvage pathway. Phosphorylated to NMN by nicotinamide riboside kinase (NRK), then converted to NAD+. Substrate for sirtuins, PARPs, and CD38. | Androgen receptor agonist driving anabolic gene transcription in muscle, bone, brain, and androgen-sensitive tissue. Aromatized to estradiol and 5-alpha-reduced to DHT, both with distinct downstream effects. |
| Legal status | OTC dietary supplement | Schedule III controlled substance (US); WADA banned |
| WADA status | allowed | banned |
| DEA / Rx | OTC supplement | Schedule III |
| Pregnancy | Insufficient data at supplement doses | Category X; contraindicated in pregnancy (virilizing effect on female fetus) |
| CAS | 1341-23-7 | 58-22-0 |
| PubChem CID | 439924 | 6013 |
| Wikidata | Q3343054 | Q150726 |
Safety profile
Nicotinamide Riboside
Common side effects
- mild GI upset (rare)
- headache (rare)
Contraindications
- pregnancy / lactation (insufficient data)
- active cancer (theoretical, no contraindicating data)
Interactions
- pterostilbene: complementary sirtuin pathway (Basis combination)(minor)
- TMG (trimethylglycine): methylation support during high NAD+ precursor dosing(minor)
Testosterone
Common side effects
- erythrocytosis
- acne
- oily skin
- fluid retention
- increased body hair
- fertility suppression
- injection-site reactions
Contraindications
- active prostate cancer
- active breast cancer
- untreated severe sleep apnea
- untreated severe BPH
- uncontrolled heart failure
- polycythemia at baseline
Interactions
- warfarin: may potentiate anticoagulant effect; monitor INR(moderate)
- insulin: may improve insulin sensitivity; monitor glucose in diabetics(moderate)
- 5-alpha reductase inhibitors (finasteride): blocks DHT conversion; reduces some androgen effects(moderate)
- aromatase inhibitors (anastrozole): lowers estradiol; risk of over-suppression(moderate)
Which Should You Take?
Nicotinamide Riboside comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Testosterone is the right call when one of the conditionals below applies.
- → If your priority is healthspan extension, pick Nicotinamide Riboside.
- → If your priority is energy and stamina, pick Nicotinamide Riboside.
- → If your priority is hormonal optimization, pick Testosterone.
- → If your priority is sexual function, pick Testosterone.
Edge case: If you want to avoid controlled substance, Nicotinamide Riboside is the more accessible choice.
Default choice: Nicotinamide Riboside. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Testosterone only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Nicotinamide Riboside and Testosterone?
Nicotinamide Riboside and Testosterone differ in category (supplement vs hormone), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Nicotinamide Riboside or Testosterone?
Nicotinamide Riboside half-life is 8 hours; Testosterone half-life is 192 hours.
Can you stack Nicotinamide Riboside with Testosterone?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper